Some ten months after submission, ProMetic Life Sciences has today announced that the FDA has cleared its Investigational New Drug application for IVIG (intravenous immunoglobulin) for the treatment of primary immunodeficiency diseases (PIDD). Despite the relatively long approval period, ProMetic is well prepared to move quickly with the majority of clinical sites for the proposed pivotal Phase III study already prepared. We understand the target date for first sales remains 2018. Given that ....